Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2023-04-03
2023-09-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.
NCT07090486
A Randomized Controlled Trial of a Digital, Self-testing Strategy for COVID-19 Infection in South Africa.
NCT05436795
Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use
NCT06734741
Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.
NCT04847622
A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.
NCT07261085
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The ubiquity of smartphones along with their data connectivity capabilities and onboard sensors make them an attractive tool to complement rapid diagnostic tests and an important component of decentralized testing. Smartphone-based tools have shown high acceptability among healthcare workers for the real-time tracking of rapid test results.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention (App) Group
Participants in this group will be given access to a COVID-19 self-testing app (SMARTest). Access to the app, given exclusively to this group, will be in addition to the 12 COVID-19 self-test kits participants receive.
SMARTest mobile app for COVID-19 self-testing
The mobile app has self-testing features and information with regard to self-testing and COVID-19.
Control (No App) Group
Participants in this group will not be given access to the COVID-19 self-testing app (SMARTest). Participants will only receive the 12 COVID-19 self-test kits.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SMARTest mobile app for COVID-19 self-testing
The mobile app has self-testing features and information with regard to self-testing and COVID-19.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years old or older
* Owns a smartphone running either Android or iOS operating systems
* Willing to download a COVID-19 self-testing app
* Willing to receive and send text messages for the study (and fill out surveys linked from text messages)
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Columbia University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yael Hirsch-Moverman
Assistant Professor of Epidemiology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yael Hirsch-Moverman, PhD
Role: PRINCIPAL_INVESTIGATOR
Columbia University
Samuel K. Sia, PhD
Role: STUDY_CHAIR
Columbia University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ICAP Harlem Prevention Center
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AAAU0815
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.